Optimizing Antibiotic Treatment for Ventilator-Associated Pneumonia
- 1 February 2006
- journal article
- research article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 26 (2) , 204-213
- https://doi.org/10.1592/phco.26.2.204
Abstract
Ventilator-associated pneumonia (VAP) is the most common infectious complication in patients receiving mechanical ventilation and accounts for exorbitant use of resources in the intensive care unit. Antimicrobial management of VAP incorporates an initial broad-spectrum, empiric regimen to ensure appropriate coverage with deescalation of therapy after 48-72 hours based on culture results and sensitivities. When VAP clinically responds to treatment, antimicrobials should be discontinued after 7-8 days to reduce overall antibiotic consumption and the selection pressure on flora observed in the intensive care unit and thus minimize the development and spread of antimicrobial resistance.Keywords
This publication has 76 references indexed in Scilit:
- Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia*Critical Care Medicine, 2005
- Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an updateJournal of Antimicrobial Chemotherapy, 2005
- Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumoniaCritical Care Medicine, 2005
- Ventilator-Associated Pneumonia in a Multi-Hospital System Differences in Microbiology by LocationInfection Control & Hospital Epidemiology, 2003
- Pharmacokinetics and Pharmacodynamics of Cefepime in Patients with Various Degrees of Renal FunctionAntimicrobial Agents and Chemotherapy, 2003
- Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center*Critical Care Medicine, 2003
- Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unitIntensive Care Medicine, 1996
- The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory CommitteeJAMA, 1995
- Risk factors for infection byPseudomonas aeruginosa in patients with ventilator-associated pneumoniaIntensive Care Medicine, 1994
- Imipenem penetration into bronchial secretionsJournal of Antimicrobial Chemotherapy, 1987